Complete response of locally advanced cutaneous squamous cell carcinoma of the eyelid to topical imiquimod 3.75

Dermatol Ther. 2022 Nov;35(11):e15800. doi: 10.1111/dth.15800. Epub 2022 Sep 14.

Authors

Francesco Toso^{1

2}, M Chiara Tronconi³, Andrea Cortese^{1

2}, Giovanni Fiorillo^{1

2}, Alessandra Bressan⁴, Antonio Costanzo^{1

2}, Riccardo G Borroni^{1

2}

Affiliations

¹ Dermatology Unit, Humanitas Research Hospital-IRCCS, Rozzano, Italy.
² Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
³ Oncology Unit, Cancer Center, Humanitas Research Hospital-IRCCS, Rozzano, Italy.
⁴ Pathology Unit, Humanitas Research Hospital-IRCCS, Rozzano, Italy.

No abstract available

Publication types

Letter

MeSH terms

Administration, Topical
Aminoquinolines / therapeutic use
Antineoplastic Agents* / therapeutic use
Carcinoma, Squamous Cell* / drug therapy
Carcinoma, Squamous Cell* / pathology
Eyelids / pathology
Humans
Imiquimod / therapeutic use
Skin Neoplasms* / drug therapy
Skin Neoplasms* / pathology
Treatment Outcome

Substances

Imiquimod
Aminoquinolines
Antineoplastic Agents